flucytosine has been researched along with losartan potassium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Deen, DF; Hu, L; Kong, EL; Lamborn, KR; Rehemtulla, A; Ruan, H; Wang, D | 1 |
2 other study(ies) available for flucytosine and losartan potassium
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.
Topics: Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cytosine Deaminase; Enhancer Elements, Genetic; Erythropoietin; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Prodrugs; Simian virus 40; Transcription Factors; Transfection; Tumor Stem Cell Assay; Yeasts | 2005 |